The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

The lawsuit followed a scathing FTC report in July that said the "dominant ... of Georgia's independent pharmacists and the need for PBM transparency." In his veto message, Kemp voiced support ...

Boston life sciences and medical device leaders agreed that the change to a Trump administration could create a more ...

“I’m proud that the FTC launched a bipartisan investigation into these shadowy middlemen, and its preliminary findings prove yet again that it’s time to bust up the PBM monopoly.” Eisai ...

As Cigna and Humana pick back up on the potential for a megamerger, executives will be keeping a close eye on the outcomes of ...

Pharmacy Benefit Managers are the middlemen who manage virtually all prescriptions written in the U.S. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities ...

Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

Michael Combs; President, Chief Executive Officer; CorVel Corp. Brandon O'Brien; Chief Financial Officer; CorVel Corp. Presentation. Operator. Thank you for standing ...

It’s the second major investigation into middlemen in the US medicines supply chain, coming after an ongoing FTC probe of pharmacy benefit management (PBM) companies, which started in 2022.

Very few users are offered the full amount advertised, and many are not given an advance at all, the FTC said in the lawsuit filed in federal court. The app appeals to users facing financial ...